Our study provided lists of potential shared neoantigens among BRCA1-related breast cancer, which may be used for developing off-the-shelf neoantigen-based vaccines, and may reflect different mutational consequences among somatic, germline BRCA1-mutated, and BRCA1-wild-type breast cancer that should be further investigated. The gene discussed is BRCA1; the disease is breast carcinoma.